Life Sciences Times, Author at Boston Life Sciences Times

eClinical Solutions Appoints Lauren Whitsell as Chief Operating Officer and Venu Mallarapu as Chief Transformation and AI Officer

March 13, 2026

Casma Therapeutics Secures $7.6 Million in MJFF Funding to Advance Parkinson’s Disease Program

March 10, 2026

NEJM Publishes Data Suggesting Zorevunersen May Modify Disease Course in Dravet Syndrome

March 5, 2026

THIS WEEK'S STORIES

WHOOP Expands Health Platform with Women’s Blood Biomarker Panel and New Cycle Insights Tools

March 10, 2026

Pretzel Therapeutics Presents Preclinical Data Supporting PX578 Development for POLG Disease

March 12, 2026

Innoviva Specialty Therapeutics Receives Strong Rating in 2026 Global Antimicrobial Resistance Benchmark

March 10, 2026

ABOUT US

Life Science Times is New England’s premier life sciences publication, covering the Pharma, Biotech, MedTech and Public Health sectors nationwide with a special focus on New England. Updated daily, we cover the latest news in everything else that touches any rubric of the rapidly growing life sciences industry.

Life Sciences Times

TOP AUTHORS

Most Read

Boston Maintains Global Life Sciences Leadership Despite Rising Lab Vacancies

Eccogene Enrolls First Patient in Phase 2a Trial Testing ECC4703 With Semaglutide for Obesity

The Hartford Expands Support for Active Minds’ Send Silence Packing Tour to Promote Student Mental Health

Form Health Launches Diabetes Program, Expanding Integrated Cardiometabolic Care for Employers

EDITOR PICKS

eClinical Solutions Appoints Lauren Whitsell as Chief Operating Officer and Venu Mallarapu as Chief Transformation and AI Officer

Casma Therapeutics Secures $7.6 Million in MJFF Funding to Advance Parkinson’s Disease Program

NEJM Publishes Data Suggesting Zorevunersen May Modify Disease Course in Dravet Syndrome

THIS WEEK'S STORIES

WHOOP Expands Health Platform with Women’s Blood Biomarker Panel and New Cycle Insights Tools

Pretzel Therapeutics Presents Preclinical Data Supporting PX578 Development for POLG Disease

Innoviva Specialty Therapeutics Receives Strong Rating in 2026 Global Antimicrobial Resistance Benchmark

POPULAR CATEGORY

ABOUT US

FOLLOW US